About retatrutide: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) and is not yet FDA-approved or commercially available. Information here reflects published Phase 2 trial data as of June 2026 and is subject to change as development continues. Luma Health currently offers compounded semaglutide and compounded tirzepatide; retatrutide is not yet available through any provider as a finished pharmaceutical product.
Understanding the side effect differences between semaglutide, tirzepatide, and investigational retatrutide can help you choose the medication most likely to be tolerable for your body, among the options that are actually available. In general, tirzepatide tends to have the lowest discontinuation rate due to side effects among GLP-1-class medications currently in clinical use, while retatrutide's additional glucagon receptor activation introduces effects not seen with the other two.
Side Effect Comparison Table
| Side Effect | Semaglutide | Tirzepatide | Retatrutide (investigational) |
|---|---|---|---|
| Nausea | 40–45% | 35–40% | 40–50% |
| Vomiting | 15–20% | 10–15% | 15–20% |
| Diarrhea | 25–30% | 15–20% | 25–30% |
| Constipation | 15–20% | 15–20% | 15–20% |
| Increased heart rate | Minimal | Minimal | Moderate (glucagon-related) |
| Feeling warm/flushed | Uncommon | Uncommon | Common (thermogenesis) |
| Discontinuation rate | ~5–7% | ~3–5% | ~5–8% |
Key Differences Explained
Semaglutide: The Most-Studied Profile
Semaglutide has the most extensive long-term safety data within the GLP-1 class. Its side effects are well-characterized and predominantly gastrointestinal. Most side effects improve within 4–8 weeks of each dose increase. Nausea tends to be worst during the first few days after each injection, gradually diminishing as the body adjusts to that dose level before the next titration step.
Tirzepatide: Generally Best Tolerated
Despite producing more weight loss on average, tirzepatide tends to have slightly lower nausea and vomiting rates than semaglutide in head-to-head comparisons. The GIP component may have a buffering effect on GLP-1-related nausea. Tirzepatide also has the lowest discontinuation rate due to side effects among medications currently in clinical use, which may partly explain its strong real-world adherence figures.
Retatrutide: Unique Glucagon Effects (Investigational)
Retatrutide's glucagon receptor activation — on top of GLP-1 and GIP — introduces side effects not seen with semaglutide or tirzepatide. The increased thermogenesis can make patients feel warm or slightly flushed. A modest increase in resting heart rate (approximately 3–5 bpm) is common in trial data. GI side effects are comparable to semaglutide but with the added complexity of three-receptor activation, consistent with its generally higher reported weight loss in Phase 2 data.
Managing Side Effects: Universal Strategies
Regardless of which GLP-1-class medication you're using, several strategies are broadly effective for managing the most common side effects:
Eat slowly, smaller portions
The most effective nausea prevention strategy for most patients.
Stay hydrated
Dehydration worsens nearly every GI side effect, especially during dose escalation.
Ginger
Has reasonable evidence for helping with GLP-1-related nausea specifically.
Titrate gradually
Don't rush dose increases — slower titration consistently reduces GI side effect severity.
Some patients also find that timing injections in the evening, rather than the morning, reduces daytime nausea. Discuss any persistent or severe side effects with your prescribing clinician rather than stopping treatment abruptly.
Why Side Effects Differ Across the GLP-1 Class
The shared core of nausea, vomiting, diarrhea, and constipation across all three medications stems from a common mechanism: GLP-1 receptor activation slows gastric emptying and affects gut motility, which is the primary driver of GI symptoms regardless of which other receptors a given medication also targets. This is why even semaglutide, the simplest of the three pharmacologically, still produces meaningful rates of these symptoms.
What differs between the medications is what's layered on top of that shared GLP-1 effect. Tirzepatide's additional GIP receptor activation appears to provide some buffering against the most severe GLP-1-related nausea, which may explain its somewhat lower rates in head-to-head data despite producing greater overall weight loss. Retatrutide's third mechanism — glucagon receptor activation — doesn't meaningfully change the GI side effect profile compared to semaglutide, but it does introduce an entirely new category of effects (thermogenesis, heart rate changes) that simply don't exist with GLP-1-only or dual GLP-1/GIP medications, since neither of those activates the glucagon pathway at all.
This pattern — side effect profile tracking with the number and type of receptors activated — is a useful general principle for understanding why next-generation GLP-1-class medications in development tend to show both somewhat higher efficacy and somewhat broader side effect profiles than their predecessors. More pharmacological activity in more pathways tends to produce more effect, both wanted and unwanted.
When to Contact Your Provider
Most GLP-1-class side effects are mild-to-moderate, concentrated during dose escalation, and improve within a few weeks at each stable dose level. However, certain symptoms warrant prompt contact with your prescribing clinician rather than waiting them out:
- Severe, persistent abdominal pain, particularly if it radiates to the back (a possible sign of pancreatitis)
- Vomiting severe enough to prevent keeping fluids down for more than 24 hours
- Signs of dehydration — dizziness, very dark urine, significantly reduced urination
- Yellowing of the skin or eyes, or right-upper-abdominal pain (possible gallbladder involvement)
- Any symptom that feels severe, sudden, or out of proportion to what you've previously experienced at that dose
Luma Health's clinical team through Wasef Health, PC is available to discuss side effects at any point during treatment — you don't need to wait for a scheduled check-in if something feels wrong.
💡 Choosing your best fit: Luma Health's clinical team through Wasef Health, PC helps match patients with the medication most likely to be tolerable for their individual profile, among the options currently available — compounded semaglutide at $90/month and compounded tirzepatide at $165/month. If you have persistent side effects on one medication, switching to the other GLP-1 option may resolve them, since the different receptor profiles mean your body may respond differently to each.
Sources & References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). NEJM. 2021;384:989–1002.
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). NEJM. 2022;387:205–216.
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT). NEJM. 2023;389:2221–2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).
Frequently Asked Questions
Among medications currently in clinical use, tirzepatide has the lowest discontinuation rate due to side effects in published trial data, making it the best-tolerated option overall on average. However, individual responses vary considerably — some patients tolerate semaglutide perfectly but struggle with tirzepatide, and vice versa.
Not necessarily. Side effects are primarily dose-dependent (higher doses generally mean more pronounced side effects) rather than purely medication-dependent. Because medications start at low doses and titrate up gradually, the side effect experience is fairly similar during the early weeks regardless of which medication you choose.
Yes. If you have persistent side effects on one medication, switching to the other available GLP-1 option may resolve them. The different receptor profiles (GLP-1-only for semaglutide vs. dual GLP-1/GIP for tirzepatide) mean your body may respond differently to each. Discuss switching with your Luma Health provider rather than stopping treatment on your own.
No. Retatrutide is investigational and not yet FDA-approved or commercially available as a finished pharmaceutical product. It remains in clinical trial development. Patients seeking GLP-1 therapy today should discuss the currently available, approved active ingredients (semaglutide and tirzepatide) with a licensed clinician.
Retatrutide's third mechanism — glucagon receptor activation, in addition to GLP-1 and GIP — increases thermogenesis (heat production) and has mild cardiac stimulant effects, which is why trial data shows patients reporting feeling warm or flushed along with a modest increase in resting heart rate. Neither semaglutide nor tirzepatide activates the glucagon receptor, so these specific effects aren't seen with the medications currently available.